Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04191834 · 1 trial · 1 indication
The FEV1 is the maximal volume of air that can be forcefully exhaled in one second
| Arm | Type | Description |
|---|---|---|
| PF-04191834 30mg | EXPERIMENTAL | - |
| PF-04191834 100mg | EXPERIMENTAL | - |
| PF-04191834 2000mg | EXPERIMENTAL | - |
| zileuton | ACTIVE_COMPARATOR | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04191834 | DRUG | 30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets. |
| zileuton | DRUG | 1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose. |
| Placebo | DRUG | 2 x placebo tablets + placebo oral dispersion, single dose. |
Inclusion Criteria: * Persistent mild/moderate asthma for at least 6 months. * Reduced lung function * Reversible airway obstruction Exclusion Criteria: * Pregnant/nursing females. * Liver function tests greater than upper limit of normal (ULN)
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-04191834 is an investigational small molecule being developed for the treatment of asthma. It is a respiratory therapeutic that has been studied in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
PF-04191834 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company conducted a Phase 2 clinical trial of the drug in patients with asthma.
PF-04191834 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a single-dose bronchodilatory study in asthma. The drug is investigational and has not been approved by regulatory authorities.
PF-04191834 has been studied in one completed Phase 2 clinical trial, identified as NCT00723021. This trial was a single-dose bronchodilatory study in asthma, conducted in the United States with 15 participants. The trial was randomized, double-blind, and placebo-controlled.
PF-04191834 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for asthma. The drug is still in clinical development and has not been authorized for marketing or use by patients.